Sandu Pharmaceuticals reported a net profit of ₹22.82 lakh for the quarter ended June 30, 2026 (Q1FY27), representing a 2.2% year-on-year increase from ₹22.33 lakh in Q1FY26. Revenue from operations declined slightly by 1.9% to ₹1,638.88 lakh, down from ₹1,669.90 lakh in the previous year’s corresponding period. The Board of Directors approved the unaudited standalone financial results on August 11, 2026, alongside the limited review report issued by statutory auditors Dileep & Prithvi Chartered Accountants.

The company’s total income stood at ₹1,640.62 lakh, while total expenses were contained at ₹1,604.57 lakh. Profit before tax was recorded at ₹36.05 lakh, compared to ₹33.87 lakh in Q1FY26. The slight dip in revenue was offset by efficient cost management, particularly in cost of materials consumed, which fell to ₹234.10 lakh from ₹191.08 lakh, though other expenses rose to ₹651.78 lakh from ₹467.73 lakh. Earnings per share (basic) increased to ₹0.37 from ₹0.23 in the prior year period.

Financial Performance Highlights

The Board also approved the Directors’ Report, Management Discussion and Analysis, Corporate Governance Report, and Secretarial Audit Report for inclusion in the Annual Report for FY26. The 41st Annual General Meeting (AGM) is scheduled for September 11, 2026, to be conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM).

Auditor Appointment and Related Party Transactions

The Board recommended the appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a first term of five consecutive years, commencing from the conclusion of the ensuing AGM until the AGM in 2031. The firm, established in 1989 and based in Mumbai, holds Peer Review Certificate No. 020259. The appointment is subject to shareholder approval at the AGM.

Additionally, the Board sought member approval for the continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited, in compliance with the Companies Act, 2013 and SEBI Listing Regulations. The Register of Members will remain closed from September 4, 2026, to September 11, 2026, with September 4 serving as the record date for dividend eligibility.

What the Numbers Show

Despite a marginal decline in top-line revenue, Sandu Pharmaceuticals managed to improve its bottom line through disciplined expense control. The profit before tax grew by 6.4%, outpacing the net profit growth of 2.2%, indicating stable tax provisions. The significant rise in earnings per share (60.9%) reflects the benefit of higher absolute profits relative to the fixed share capital of 966.10 lakh shares. This performance underscores operational resilience in the Ayurvedic proprietary medicines segment during the initial quarter of FY27.

Sandu Pharmaceuticals Limited has redesignated Shri Balram Viswanathan as Chairman and Managing Director for a term of three years effective July 11, 2026. The board also appointed Dr. Neeti Madan Kapre as an Additional Non-Executive Independent Director for a five-year term. These decisions follow the demise of former Managing Director Shri Umesh B. Sandu on June 19, 2026.

Board Appointments and Redesignations

The board approved the redesignation of Shri Balram Viswanathan from Chairman and Non-Executive Independent Director to Chairman and Managing Director. His appointment is subject to shareholder approval at the ensuing general meeting. Additionally, Dr. Neeti Madan Kapre was appointed as an Additional Non-Executive Independent Director effective July 11, 2026, until July 10, 2031, subject to shareholder approval.

Committee Reconstitution and Policy Updates

Pursuant to the leadership changes, the board reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee. The board also revised the Vigil Mechanism Policy to replace the name of the late Shri Umesh B. Sandu with Shri Balram Viswanathan as the Chairman and Managing Director.

Key Appointments Summary

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.